Explore
Validate
Learn
Western blot
ImmunoprecipitationAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 16-9823-82 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- LAP (Latency Associated peptide) Monoclonal Antibody (VB3A9), Functional Grade, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: This VB3A9 monoclonal antibody recognizes human latency-associated peptide (LAP), also known as the TGF-beta propeptide. Human LAP is a homodimer of 65-75 kDa that is non-covalently associated with TGF-beta and this complex is also referred to as the small latent complex (SLC). LAP can be covalently associated with latent TGF-beta binding proteins (LTBP) through disulfide bonds, forming the large latent complex (LLC). The association of LAP with TGF-beta facilitates its secretion and also renders TGF-beta inactive. VB3A9 has been reported to cross-react with non-human primate LAP, but does not cross-react with mouse LAP. Applications Reported: This VB3A9 antibody has been reported for use in immunoblotting (WB) and immunoprecipitation. Applications Tested: This VB3A9 antibody has been tested by immunoblot analysis of human platelets under reducing conditions at 5 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 µm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- VB3A9
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- 4° C
Submitted references Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1.
Annes JP, Chen Y, Munger JS, Rifkin DB
The Journal of cell biology 2004 Jun 7;165(5):723-34
The Journal of cell biology 2004 Jun 7;165(5):723-34
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoblot analysis of lysate from normal human platelets run on SDS-PAGE under reducing conditions. The membrane was probed with 5 µg/mL Anti-Human LAP (VB3A9) followed by Anti-Mouse IgG HRP.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3. Affect of ECR3E on alpha V beta 6 -mediated latent TGF-beta activation and LLC formation. CHO/beta 6 cells were transduced with empty, ECR3E- or ECR4E-expressing viruses. (A) The transduced cells were co-cultured with TGF-beta-reporter TMLCs for 16-24 h before harvesting cell lysates and measuring luciferase activity. Experiments were performed in triplicate and the SDs of a single experiment are given. The errors bars represent the SD of a single experiment that was performed in triplicate. This experiment was repeated multiple times with similar results. (B) The transduced cells were transiently transfected with a TGF-beta1 cDNA expression vector and allowed to generate CM for 16-24 h. The media were used for Western blotting. The reactive bands were revealed with an anti-LAP antibody (Vb3A9).
